To the core

Rosendaal, Frits R.; Reitsma, P. H.

doi:10.1111/jth.13231

Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.

Journal of Thrombosis and Haemostasis

2016

DOI: 10.1111/jth.13231

|View full text |Cite

To the core

Frits R. Rosendaal

P. H. Reitsma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Association of Remote History of Venous Thrombosis With Risk of Venous Thrombosis After Age 70 Years

et al. 2022

View full text Add to dashboard Cite

show abstract

Association of Remote History of Venous Thrombosis With Risk of Venous Thrombosis After Age 70 Years

et al. 2022

View full text Add to dashboard Cite

show abstract

Atherosclerotic plaque injury-mediated murine thrombosis models: advantages and limitations

et al. 2020

View full text Add to dashboard Cite

In spite of current treatment strategies, myocardial infarction and stroke are still major causes of death worldwide. These events are triggered by damage of an atherosclerotic plaque, resulting in occlusive thrombus formation. Mouse studies have significantly contributed to our understanding of the mechanisms of atherogenesis and of thrombosis following plaque injury, but the extent to which the mouse serves as an accurate model of human disease is open to discussion. In this review, we provide a detailed overview and comparison of the described mouse models for atherothrombosis including their (dis)advantages. Herein guidance is provided on how to select a suitable atherothrombosis model for research questions primarily relevant to the field of thrombosis.

show abstract

Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review

Vathiotis

Syrigos

Dimakakos

2021

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Low-molecular-weight heparins are approved for primary and secondary venous thromboembolism prevention. Tinzaparin is the low-molecular-weight heparin with the highest average molecular weight. The purpose of this systematic review is to provide an update regarding the safety profile of tinzaparin, prescribed either as a prophylactic or as a therapeutic regimen for venous thromboembolism in special populations, including cancer patients and patients with renal impairment. We identified prospective studies up to August 2020 reporting safety outcomes for cancer patients and patients with renal impairment on tinzaparin regimens. In patients with cancer major bleeding rates fluctuated between 0.8% and 7%. Patients on tinzaparin exhibited significantly lower rates of clinically relevant nonmajor bleeding events in comparison with those on vitamin K antagonists. Bioaccumulation of tinzaparin was not correlated with age, body weight or creatinine clearance. Periodic administration of either prophylactic or therapeutic doses of tinzaparin did not result in bioaccumulation, even in patients with severe renal impairment and creatinine clearance < 20 ml/min. Major bleeding rates for non-cancer patients with renal impairment on prophylactic tinzaparin regimens were 0%. Non-cancer patients with renal impairment on therapeutic tinzaparin regimens exhibited major bleeding in 0 to 3.4% of cases; major bleeding rates were higher for cancer patients with renal impairment on therapeutic tinzaparin regimens (4.3 to 10%). Tinzaparin can be used without dose adjustment in patients with severe renal impairment and creatinine clearance > 20 ml/min. Tinzaparin represents a safe choice for special populations at increased risk for thrombosis and bleeding.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

To the core

Cited by 3 publications

References 0 publications

Association of Remote History of Venous Thrombosis With Risk of Venous Thrombosis After Age 70 Years

Association of Remote History of Venous Thrombosis With Risk of Venous Thrombosis After Age 70 Years

Atherosclerotic plaque injury-mediated murine thrombosis models: advantages and limitations

Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review

Contact Info

Product

Resources

About